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Acute management of people who have had a myocardial infarction (MI) has changed dramatically, with more people surviving. More effective treatment, including percutaneous coronary intervention, raises questions about the relevance of current recommendations on secondary prevention. Concerns have arisen about the need for the antiplatelet regimens mandated by coronary stent insertion in people who have an independent need for warfarin. New data are also available about how to increase attendance for cardiac rehabilitation programmes, about existing drug treatments and lifestyle advice, and new antithrombotic agents.
The impact of shorter stays in hospital on the changes in acute management have emphasised the importance of primary care in secondary prevention. General practitioners and nurses are now responsible for most of this activity, specifically the promotion of cardiac rehabilitation programmes and the prescription and monitoring of ongoing drug therapy. This also requires effective communication between hospital and primary care, ensuring that clear management plans are relayed in a timely way.
These considerations have led to a revision of the 2007 guideline on secondary prevention after an MI.
1 This article summarises the most recent recommendations from the National Institute for Health and Care Excellence (NICE).
2 Recommendations NICE recommendations are based on systematic reviews of best available evidence and explicit consideration of cost effectiveness. When minimal evidence is available, recommendations are based on the Guideline Development Group's experience and opinion of what constitutes good practice. Evidence levels for the recommendations are in the full version of this article on bmj.com.
Cardiac rehabilitation
Cardiac rehabilitation should be offered to all people who have had an MI and should be provided in different settings (such as in the person's home) and at different times of the day to ensure that people can attend and complete the programme.
• Offer cardiac rehabilitation programmes designed to motivate people to attend and complete the programme. Explain the benefits of attending (which include reducing the risk of death and of having another MI, and improving quality of life). (New recommendation.) • Begin cardiac rehabilitation as soon as possible after admission and before discharge from hospital. Invite the person to a cardiac rehabilitation session starting within 10 days of their discharge from hospital. (New recommendation.)
GUIDELINES
Secondary prevention for patients after a myocardial infarction: summary of updated NICE guidance • Advise all people who smoke to stop and offer assistance from a smoking cessation service in line with NICE public health guidance on brief interventions and referral for smoking cessation (PH1).
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• Advise people to eat a Mediterranean-style diet (more bread, fruit, vegetables, and fish; less meat; and replace butter and cheese with products based on plant oils).
• After an MI, offer all patients who are overweight or obese advice and support to achieve and maintain a healthy weight in line with NICE clinical guideline on obesity (CG43).
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• Advise people who drink alcohol to keep weekly consumption within safe limits (no more than 21 units of alcohol per week for men, or 14 units per week for women) and to avoid binge drinking (more than 3 alcoholic drinks in 1-2 hours).
• Advise people to be physically active for 20-30 minutes a day to the point of slight breathlessness. Advise people who are not active to this level to increase their activity in a gradual, stepwise manner, with the aim of increasing their exercise capacity. They should start at a level that is comfortable and increase the duration and intensity of activity as they gain fitness.
• Do not recommend routinely eating oily fish for the • Ticagrelor in combination with low dose aspirin for up to 12 months is recommended as another treatment option to adults with acute coronary syndromes: -Those with ST segment elevation MI whom cardiologists intend to treat with primary percutaneous coronary intervention -Those with Non-ST segment elevation MI.
(New recommendation.)
• Offer clopidogrel in combination with low dose aspirin for at least one month and consider continuing for up to 12 months for people who have had an ST segment elevation MI for which they received medical management, with or without reperfusion treatment using a fibrinolytic agent. 
Communication of diagnosis and advice
• Offer a copy of the discharge summary for all people who have had an MI.
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Overcoming barriers
Implementation of these recommendations will be challenging throughout the healthcare system. Cardiac rehabilitation services need to ensure that people who have had an MI are offered their first cardiac rehabilitation session within 10 days of hospital discharge, and make arrangements to offer further appointments to non-attenders. Hospital services need to review drug policies-particularly around antiplatelet agents, prescribing for people with an independent indication for anticoagulation, and 
What is the next investigation?
Background Hypokalaemia is defined as a serum potassium below 3.5 mmol/L and is commonly graded as mild (3.1-3.5 mmol/L), moderate (2.5-3.0 mmol/L), and severe (<2.5 mmol/L).
1
Hypokalaemia is a common finding in the general population; a community based cohort study of 5200 adults over 55 years in the Netherlands showed a 3% prevalence of mild hypokalaemia. 2 It is much more common in hospital populations, with one episode of severe hypokalaemia per week in an observational study at a UK secondary care hospital with a catchment population of 150 000.
3

LEARNING POINTS
The cause of hypokalaemia is usually obvious from the history and is most often diuretic drugs or gastrointestinal loss Severe hypokalaemia (<2.5 mmol/L) is associated with life threatening arrhythmias and should be treated in an acute facility with electrocardiographic monitoring If hypokalaemia is moderate or severe, or its cause unclear, consider checking serum and urine electrolytes, renal function, and acid base balance Refer patients with no obvious explanation for their hypokalaemia for endocrine or renal assessment About 98% of the body's potassium is intracellular, 4 and the intracellular-extracellular potassium gradient is crucial to maintaining resting membrane potential and normal nerve and muscle function. Small decreases in extracellular potassium can have serious effects on the heart and skeletal muscles. Mild hypokalaemia is often asymptomatic and picked up on routine blood tests, but severe hypokalaemia is associated with life threatening arrhythmias and sudden cardiac death. In a double blind randomised controlled trial, hypertensive men treated with thiazide diuretics who developed a serum potassium of 3 mmol/L or less had a twofold increase in ventricular arrhythmias compared with those with normal serum potassium.
PRACTICE
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Is the patient safe? Because severe hypokalaemia can cause fatal arrhythmias, the first question to answer is whether the patient is in immediate danger (figure). If serum potassium is severely low (<2.5 mmol/L), or if there are symptoms of severe hypokalaemia (such as muscle weakness, syncope, or palpitations), evaluate and treat the patient urgently in an acute facility with cardiac monitoring.
6 Initial assessment of moderate or severe hypokalaemia should include electrocardiography, which may show small T waves, ST depression, prominent U waves, or a prolonged QT interval. Patients with rapid onset of hypokalaemia, concomitant risk factors (especially digoxin treatment, left ventricular hypertrophy, or heart failure), and electrocardiographic changes are at increased risk of serious arrhythmias.
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The next step is to take a detailed history and examination of the patient. The main laboratory investigations are assessment of serum and urine electrolytes and acid-base balance.
History
The history often helps clarify the likely cause of hypokalaemia. Gastrointestinal symptoms and a history of diuretic treatment are important because a retrospective observational study found that most cases of hypokalaemia are associated with vomiting or diarrhoea (51%) or diuretics (47%).
3 Reduced oral intake alone rarely causes hypokalaemia in healthy people but is a contributing factor in more than a third of inpatients with severe hypokalaemia.
3 Also ask about a history of excessive alcohol intake, chronic laxative misuse, or liquorice ingestion.
Any process that stimulates uptake of potassium from the extracellular fluid into cells can cause hypokalaemia. This is common after intravenous insulin for treatment of hyperglycaemia (in particular, diabetic ketoacidosis), but stimulation of sympathetic β2 receptors (for example, with high dose salbutamol) and verapamil overdose can have a similar effect. Uptake of potassium by rapidly dividing cells-for example, after vitamin B 12 or folate replacement in megaloblastic anaemia-can also cause hypokalaemia. In patients with a history of muscle weakness (typically after strenuous exercise or a large carbohydrate meal) and severe hypokalaemia, consider the possibility of hypokalaemic periodic paralysis or thyrotoxic periodic paralysis (if symptoms of thyrotoxicosis are also present, particularly in Asian men).
Physical examination
Look for flaccid muscle weakness and signs of arrthymias. Check blood pressure because hypertension in association with hypokalaemia may suggest primary hyperaldosteronism or Cushing's syndrome. In this last scenario, clinical features of steroid excess-such as central obesity, bruises, and proximal muscle weakness or wasting-may be evident. Signs of dehydration, hypotension, and Kussmaul breathing in a patient with diabetes are suggestive of diabetic ketoacidosis.
Laboratory investigations
In mild hypokalaemia with an obvious cause, laboratory investigations will be limited to monitoring serum potassium concentrations. However, if hypokalaemia is moderate or severe, or the cause of hypokalaemia is unclear, initial basic laboratory investigations should include sodium, potassium, creatinine, urea, magnesium, glucose, and bicarbonate (figure). Spurious hypokalaemia may occur due to in vitro redistribution-for example, potassium uptake by large numbers of abnormal white cells in leukaemia when the sample is left at room temperature. If this is suspected, send a fresh blood sample to the laboratory for reanalysis of potassium, making sure that the sample arrives rapidly after venepuncture. 
Assessment of acid-base balance
Assessment of magnesium
An assessment of serum magnesium is important because hypokalaemia and hypomagnesaemia often coexist, and treatment of hypokalaemia is unlikely to be successful without reversal of hypomagnesaemia.
10 Check magnesium if the cause of hypokalaemia is not obvious or hypokalaemia is moderate to severe.
When to refer?
Severe hypokalaemia warrants referral to an acute hospital. Refer patients with ongoing hypokalaemia with no explanation for specialist endocrine or renal assessment.
Other specialised tests After referral, specialised tests are sometimes needed to determine the cause of hypokalaemia. The assessment of plasma aldosterone to renin ratio is considered the most reliable tool for investigating primary hyperaldosteronism, with a retrospective study showing a sensitivity and specificity of 97% and 94%, respectively. 11 This ratio is raised in primary hyperaldosteronism and should be assessed in patients presenting with hypertension and unexplained hypokalaemia.
Patients with hypokalaemia and clinical features of steroid excess should undergo screening tests (such as 24 hour urinary cortisol, overnight dexamethasone suppression test, or midnight salivary cortisol) for Cushing's syndrome.
12 Check thyroid function tests (serum thyroid stimulating hormone and free thyroxine) if thyrotoxic periodic paralysis is suspected.
Outcome
The patient was referred to a renal clinic for assessment and was found to have high serum bicarbonate (34 mmol/L; reference range 22-30). Hypokalaemia and metabolic alkalosis fitted with either upper gastrointestinal potassium loss or renal potassium loss due to diuretics, Bartter's syndrome, or Gitelman's syndrome. A normal blood pressure made mineralocorticoid excess an unlikely cause. A urinary KCR of less than 2.5 mmol/ mmol suggested non-renal potassium loss. Serum chloride was low at 84 mmol/L (reference range 95-108), which fitted with upper gastrointestinal fluid loss. On closer questioning, with the knowledge of these results, the patient confessed to recurrent self induced vomiting to help with weight loss.
